Next Generation Biomaterials for Islet Delivery and Immune Acceptance for Diabetes

Timeslot: Thursday, April 12, 2018 - 1:45pm to 3:45pm
Track: Biomaterials for Immunity and Cancer
Room: 210/211

About

Type 1 diabetes is an autoimmune disease in which the insulin-producing beta cells of the pancreas are destroyed. Transplantation of pancreatic islet cells isolated from donors has emerged as a promising strategy for the treatment of type 1 diabetes. However, this strategy is severely limited by islet loss due to inflammation, inadequate blood supply, and immune rejection. Biomaterial technologies are absolutely critical to the successful widespread application of islet transplantation in humans. This symposium will focus on novel biomaterials and technologies to improve islet survival and function. Examples include (i) new immune-directing encapsulating polymers, (ii) materials delivering immunomodulatory agents, and (iii) biomaterials addressing hypoxia, inflammation, and vascularization.

Abstracts

  • 1:45 p.m. 246. Invited Speaker: Cherie Stabler, PhD, University of Florida

  • 2:15 p.m. 247. Design of degradable PEG hydrogels to deliver CCL21 and ? cell autoantigens for the induction of peripheral tolerance in type 1 diabetes, S Zustiak(1), A Tomei(2), D Velluto(2), M Abreu(2), A Stock*(2); (1)Saint Louis University, Saint Louis, MO, (2)University of Miami, Miami, FL

  • 2:30 p.m. 248. The timing is crucial for adequate blood perfusion of an artificial subcutaneous site for pancreatic islet transplantation, A. Patikova*, L. Kosinova, A. Vojtiskova, E. Sticova, J. Kriz; Institute for Clinical and Experimental Medicine, Prague, Czech Republic

  • 2:45 p.m. 249. Enzymatic peptide ligation for in situ encapsulation and delivery of pancreatic islets, M Arkenberg*, C Lin; Indiana University Purdue University Indianapolis, Lebanon, IN

  • 3:00 p.m. 250. Clinically Translatable Immunomodulatory Cytokine Eluting Alginate Microbeads containing Neonatal Porcine Islet-like Clusters for the Treatment of Type 1 Diabetes, P Varde*(1), J Hutcheson(1), K Buac(1), J Cano(1), B Denney(1), K Grooms(1), C Seawell(1), R Rodriguez(1), M Poznansky(2), S McCormack(1), S Chavan(1); (1)ViCapsys Inc., Athens, GA, (2)The Vaccine and Immunotherapy Center, Massachusetts General Hospital,

  • 3:15 p.m. 251. Subcutaneous transplantation of reconstituted pseudo-islets to restore normoglycemia in diabetic SCID/bg mice, A Vlahos*, S Keshavjee, S Kinney, A Martyts, M Sefton; University of Toronto, Toronto, ON

  • 3:30 p.m. 252. Microfluidic Poly(ethylene glycol)-based Islet Encapsulation Enables Transplantation in Highly Vascularized Site, J Weaver*, D Headen, M Coronel, M Hunckler, A Garcia; Georgia Institute of Technology, Atlanta, GA

Invited Speaker(s)